



sponsor

[← Back to Conference Coverage \(/internal-medicine/conference-abstracts.cfm/35308/?nonus=0&searchstring=&coverage\\_day=0&page=2\)](#)



## Efficacy of HPV vaccination in HIV+ adolescents and young adults for the induction of strong HPV-specific humoral and cell-mediated immune responses

*V Rainone, D Trabattoni, F Penagini, V Fabiano, V Giacomet, A Viganò, M Clerici, GV Zuccotti*

**20th International AIDS Conference (AIDS 2014) (/internal-medicine/conference-abstracts.cfm/35308/?nonus=0&searchstring=&coverage\_day=0&page=2)**

Melbourne, Australia | July 23, 2014

**Summary:** Human Papilloma Virus (HPV)-associated ano-genital infections represent the most common sexually transmitted disease in the general population. The incidence of HPV-associated cancers has been increasing in HIV-infected patients. HPV vaccination may be an important approach to reduce the risk of HPV-associated cancers in HIV-infected patients and a combined strategy of screening and HPV vaccination may guarantee a more adequate prevention of HPV-associated lesions. Immunogenicity of HPV vaccines in HIV-infected patients is still not adequately evaluated. Study authors analysed immunogenicity of a quadrivalent HPV vaccine in HIV-infected patients without baseline molecular evidence of vaccine-type HPV infection focusing on both HPV-specific cell-mediated (CMI) and humoral immunity. They found that quadrivalent HPV-16/18/6/11 VLP vaccine induces strong HPV-specific cell-mediated and humoral immune responses in ARV-treated HIV-infected individuals that are comparable to those observed in HIV-seronegative controls. HPV-specific CMI is likely an important component of the protective effect of this vaccine, beside the generation of a broad antibody response, data herein indicating that this arm of immunity is not impaired in ARV-treated HIV infected individuals.


### Methods:

- 31 ARV-treated HIV-infected adolescents (age range 28-14 years, mostly with undetectable viremia and effective CD4 recovery) and 25 sex- and age-matched HIV-seronegative healthy controls were enrolled in the study.
- Quadrivalent HPV-16/18/6/11 VLP vaccine (Gardasil®) was administered 3 times (baseline, 2 months and 6 months).
- Immune activation (CD4/CD25/HLADRII, CD8/CD25/HLADRII), na<sup>?</sup>ve, effector and memory T-cell patterns, cellular immune responses (CD4/IFN- $\gamma$ /IL-2, CD8/IFN- $\gamma$ /TNF- $\alpha$ , CD8/Perforin/GranzymeB) and anti-HPV16/18/6/11 IgG titers were evaluated at baseline and after each immunization.

### Results:

- After the third immunization, HIV-infected individuals showed: 1) no changes in CD4 counts, percentage of CD4 cells and HIV viral load; 2) a significant increase in na<sup>?</sup>ve CD8 T-cells, activated CD8 T-cells and in central memory CD4 and CD8 T-cells; 3) a significant reduction in terminally differentiated CD8 T-cells; 4) a significant increase in unstimulated and in HPV-specific IL2+/CD4+, IFN- $\gamma$ /CD4+, IFN- $\gamma$ /CD8+ and TNF- $\alpha$ /CD8+ T-cells; 5) a significant increase in HPV-specific Perforin- and Granzyme B-secreting CD8 T-cells.
- High titers of anti-HPV16/18/6/11 IgG rose shortly after the first immunization and increased over time until the last immunization.
- Notably, results obtained in HIV-infected patients were comparable to those seen in HC.

)&searchstring=&coverage\_day=0&page=2)



sponsor